Answers are grounded in this paper and cite their sources.
Microparticle-based vaccination induces strong immune responses in a viral infection, suggesting innovative vaccination methods.
PLGA microparticle-based vaccination induces potent systemic and mucosal immune responses against SARS-CoV-2 RBD. This adaptable platform represents a promising approach for mucosal vaccination strategies, with potential for rapid adaptation to emerging variants.
No takes yet. Share an insight, caveat, or question.
Horvath et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: